Real-world efficacy and problems of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) in Japanese patients with asthma

Real-world efficacy and problems of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) in Japanese patients with asthma

Objective: The Japanese drug use system allowed the “once-daily use” of inhaled corticosteroid (ICS) fluticasone furoate (FF) combined with a long acting beta-2 agonist (LABA) vilanterol (VI) against asthma for the first time in 2013. Until then, patients with asthma had to use ICS at least twice-da...

Full description

Bibliographic Details
Main Authors: Akira Umeda, Tateki Yamane, Taichi Mochizuki, Yasushi Inoue, Kenji Tsushima, Kazuya Miyagawa, Atsumi Mochida, Hiroshi Takeda, Yasumasa Okada, Koich Fukunaga
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:Cogent Medicine
Subjects:
once-daily
inhaled corticosteroid
fluticasone furoate
vilanterol
airflow
asthma
Online Access:http://dx.doi.org/10.1080/2331205X.2019.1600632

Similar Items

Similar Items